Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease

Jee Fu Huang; Pei Chien Tsai; Ming Lun Yeh; Chung Feng Huang; Ching I. Huang; Mei Hsuan Lee; Po Yau Hsu; Chih Wen Wang; Yu Ju Wei; Po Cheng Liang; Yi Hung Lin; Meng Hsuan Hsieh; Jeng Fu Yang; Ming Yen Hsieh; Tyng Yuan Jang; Ming Jong Bair; Zu Yau Lin; Chia Yen Dai; Ming Lung Yu; Wan Long Chuang

doi:10.14218/JCTH.2022.00103S

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease

Jee Fu Huang, Pei Chien Tsai, Ming Lun Yeh, Chung Feng Huang, Ching I. Huang, Mei Hsuan Lee, Po Yau Hsu, Chih Wen Wang, Yu Ju Wei, Po Cheng Liang, Yi Hung Lin, Meng Hsuan Hsieh, Jeng Fu Yang, Ming Yen Hsieh, Tyng Yuan Jang, Ming Jong Bair, Zu Yau Lin, Chia Yen Dai, Ming Lung Yu^*, Wan Long Chuang^*

^*Corresponding author for this work

Institute of Clinical Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background and Aims: Disease severity across the different diagnostic categories of metabolic dysfunction-associat-ed fatty liver disease (MAFLD) remains elusive. This study assessed the fibrosis stages and features of MAFLD between different items. We also aimed to investigate the associations between advanced fibrosis and risk factors. Methods: This multicenter cross-sectional study enrolled adults participat-ing in liver disease screening in the community. Patients were stratified following MAFLD diagnostic criteria, to group A (395 patients) for type 2 diabetes, group B (1,818 patients) for body mass index (BMI)>23 kg/m², and group C (44 patients) for BMI≤23 kg/m² with at least two metabolic factors. Advanced fibrosis was defined as a fibrosis-4 index>2.67. Re-sults: Between 2009 and 2020, 1,948 MAFLD patients were recruited, including 478 with concomitant liver diseases. Advanced fibrosis was observed in 125 patients. A significantly larger proportion of patients in group C (25.0%) than in group A (7.6%) and group B (5.8%) had advanced fibrosis (p<0.01). Logistic regression analysis found that hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection (odds ra-tio [OR]: 12.14, 95% confidence interval [CI]: 4.04–36.52; p<0.01), HCV infection (OR: 7.87, 95% CI: 4.78–12.97; p<0.01), group C (OR: 6.00, 95% CI: 2.53–14.22; p<0.01), and TC/LDL-C (OR: 1.21, 95% CI: 1.06–1.38; p<0.01) were significant predictors of advanced fibrosis. Conclusions: A higher proportion of lean MAFLD patients with metabolic ab-normalities had advanced fibrosis. HCV infection was significantly associated with advanced fibrosis.

Original language	English
Pages (from-to)	1061-1068
Number of pages	8
Journal	Journal of Clinical and Translational Hepatology
Volume	11
Issue number	5
DOIs	https://doi.org/10.14218/JCTH.2022.00103S
State	Published - 2023

Keywords

Advanced fibrosis
Community screening
Fibrosis-4 in-dex
Metabolic dysfunction-associated fatty liver disease
Viral hepatitis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.14218/JCTH.2022.00103S

Cite this

Huang, J. F., Tsai, P. C., Yeh, M. L., Huang, C. F., Huang, C. I., Lee, M. H., Hsu, P. Y., Wang, C. W., Wei, Y. J., Liang, P. C., Lin, Y. H., Hsieh, M. H., Yang, J. F., Hsieh, M. Y., Jang, T. Y., Bair, M. J., Lin, Z. Y., Dai, C. Y., Yu, M. L., & Chuang, W. L. (2023). Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 11(5), 1061-1068. https://doi.org/10.14218/JCTH.2022.00103S

@article{fc8c7ebb743645c2a06a6e12604f69b1,

title = "Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease",

abstract = "Background and Aims: Disease severity across the different diagnostic categories of metabolic dysfunction-associat-ed fatty liver disease (MAFLD) remains elusive. This study assessed the fibrosis stages and features of MAFLD between different items. We also aimed to investigate the associations between advanced fibrosis and risk factors. Methods: This multicenter cross-sectional study enrolled adults participat-ing in liver disease screening in the community. Patients were stratified following MAFLD diagnostic criteria, to group A (395 patients) for type 2 diabetes, group B (1,818 patients) for body mass index (BMI)>23 kg/m2, and group C (44 patients) for BMI≤23 kg/m2 with at least two metabolic factors. Advanced fibrosis was defined as a fibrosis-4 index>2.67. Re-sults: Between 2009 and 2020, 1,948 MAFLD patients were recruited, including 478 with concomitant liver diseases. Advanced fibrosis was observed in 125 patients. A significantly larger proportion of patients in group C (25.0%) than in group A (7.6%) and group B (5.8%) had advanced fibrosis (p<0.01). Logistic regression analysis found that hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection (odds ra-tio [OR]: 12.14, 95% confidence interval [CI]: 4.04–36.52; p<0.01), HCV infection (OR: 7.87, 95% CI: 4.78–12.97; p<0.01), group C (OR: 6.00, 95% CI: 2.53–14.22; p<0.01), and TC/LDL-C (OR: 1.21, 95% CI: 1.06–1.38; p<0.01) were significant predictors of advanced fibrosis. Conclusions: A higher proportion of lean MAFLD patients with metabolic ab-normalities had advanced fibrosis. HCV infection was significantly associated with advanced fibrosis.",

keywords = "Advanced fibrosis, Community screening, Fibrosis-4 in-dex, Metabolic dysfunction-associated fatty liver disease, Viral hepatitis",

author = "Huang, {Jee Fu} and Tsai, {Pei Chien} and Yeh, {Ming Lun} and Huang, {Chung Feng} and Huang, {Ching I.} and Lee, {Mei Hsuan} and Hsu, {Po Yau} and Wang, {Chih Wen} and Wei, {Yu Ju} and Liang, {Po Cheng} and Lin, {Yi Hung} and Hsieh, {Meng Hsuan} and Yang, {Jeng Fu} and Hsieh, {Ming Yen} and Jang, {Tyng Yuan} and Bair, {Ming Jong} and Lin, {Zu Yau} and Dai, {Chia Yen} and Yu, {Ming Lung} and Chuang, {Wan Long}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s).",

year = "2023",

doi = "10.14218/JCTH.2022.00103S",

language = "English",

volume = "11",

pages = "1061--1068",

journal = "Journal of Clinical and Translational Hepatology",

issn = "2225-0719",

publisher = "Xia and He Publishing Inc.",

number = "5",

}

Huang, JF, Tsai, PC, Yeh, ML, Huang, CF, Huang, CI, Lee, MH, Hsu, PY, Wang, CW, Wei, YJ, Liang, PC, Lin, YH, Hsieh, MH, Yang, JF, Hsieh, MY, Jang, TY, Bair, MJ, Lin, ZY, Dai, CY, Yu, ML & Chuang, WL 2023, 'Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease', Journal of Clinical and Translational Hepatology, vol. 11, no. 5, pp. 1061-1068. https://doi.org/10.14218/JCTH.2022.00103S

TY - JOUR

T1 - Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease

AU - Huang, Jee Fu

AU - Tsai, Pei Chien

AU - Yeh, Ming Lun

AU - Huang, Chung Feng

AU - Huang, Ching I.

AU - Lee, Mei Hsuan

AU - Hsu, Po Yau

AU - Wang, Chih Wen

AU - Wei, Yu Ju

AU - Liang, Po Cheng

AU - Lin, Yi Hung

AU - Hsieh, Meng Hsuan

AU - Yang, Jeng Fu

AU - Hsieh, Ming Yen

AU - Jang, Tyng Yuan

AU - Bair, Ming Jong

AU - Lin, Zu Yau

AU - Dai, Chia Yen

AU - Yu, Ming Lung

AU - Chuang, Wan Long

PY - 2023

Y1 - 2023

N2 - Background and Aims: Disease severity across the different diagnostic categories of metabolic dysfunction-associat-ed fatty liver disease (MAFLD) remains elusive. This study assessed the fibrosis stages and features of MAFLD between different items. We also aimed to investigate the associations between advanced fibrosis and risk factors. Methods: This multicenter cross-sectional study enrolled adults participat-ing in liver disease screening in the community. Patients were stratified following MAFLD diagnostic criteria, to group A (395 patients) for type 2 diabetes, group B (1,818 patients) for body mass index (BMI)>23 kg/m2, and group C (44 patients) for BMI≤23 kg/m2 with at least two metabolic factors. Advanced fibrosis was defined as a fibrosis-4 index>2.67. Re-sults: Between 2009 and 2020, 1,948 MAFLD patients were recruited, including 478 with concomitant liver diseases. Advanced fibrosis was observed in 125 patients. A significantly larger proportion of patients in group C (25.0%) than in group A (7.6%) and group B (5.8%) had advanced fibrosis (p<0.01). Logistic regression analysis found that hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection (odds ra-tio [OR]: 12.14, 95% confidence interval [CI]: 4.04–36.52; p<0.01), HCV infection (OR: 7.87, 95% CI: 4.78–12.97; p<0.01), group C (OR: 6.00, 95% CI: 2.53–14.22; p<0.01), and TC/LDL-C (OR: 1.21, 95% CI: 1.06–1.38; p<0.01) were significant predictors of advanced fibrosis. Conclusions: A higher proportion of lean MAFLD patients with metabolic ab-normalities had advanced fibrosis. HCV infection was significantly associated with advanced fibrosis.

AB - Background and Aims: Disease severity across the different diagnostic categories of metabolic dysfunction-associat-ed fatty liver disease (MAFLD) remains elusive. This study assessed the fibrosis stages and features of MAFLD between different items. We also aimed to investigate the associations between advanced fibrosis and risk factors. Methods: This multicenter cross-sectional study enrolled adults participat-ing in liver disease screening in the community. Patients were stratified following MAFLD diagnostic criteria, to group A (395 patients) for type 2 diabetes, group B (1,818 patients) for body mass index (BMI)>23 kg/m2, and group C (44 patients) for BMI≤23 kg/m2 with at least two metabolic factors. Advanced fibrosis was defined as a fibrosis-4 index>2.67. Re-sults: Between 2009 and 2020, 1,948 MAFLD patients were recruited, including 478 with concomitant liver diseases. Advanced fibrosis was observed in 125 patients. A significantly larger proportion of patients in group C (25.0%) than in group A (7.6%) and group B (5.8%) had advanced fibrosis (p<0.01). Logistic regression analysis found that hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection (odds ra-tio [OR]: 12.14, 95% confidence interval [CI]: 4.04–36.52; p<0.01), HCV infection (OR: 7.87, 95% CI: 4.78–12.97; p<0.01), group C (OR: 6.00, 95% CI: 2.53–14.22; p<0.01), and TC/LDL-C (OR: 1.21, 95% CI: 1.06–1.38; p<0.01) were significant predictors of advanced fibrosis. Conclusions: A higher proportion of lean MAFLD patients with metabolic ab-normalities had advanced fibrosis. HCV infection was significantly associated with advanced fibrosis.

KW - Advanced fibrosis

KW - Community screening

KW - Fibrosis-4 in-dex

KW - Metabolic dysfunction-associated fatty liver disease

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85167709813&partnerID=8YFLogxK

U2 - 10.14218/JCTH.2022.00103S

DO - 10.14218/JCTH.2022.00103S

M3 - Article

AN - SCOPUS:85167709813

SN - 2225-0719

VL - 11

SP - 1061

EP - 1068

JO - Journal of Clinical and Translational Hepatology

JF - Journal of Clinical and Translational Hepatology

IS - 5

ER -

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this